Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 77, Issue 2, 2018, Pages 289-292

  Kavanaugh, Arthur ^a   Van Vollenhoven, Ronald F ^b   Fleischmann, Roy ^c   Emery, Paul ^d,e   Sainsbury, Iain ^f   Florentinus, Stefan ^f   Chen, Su ^f   Guérette, Benoît ^f   Kupper, Hartmut ^f   Smolen, Josef S ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Amsterdam Rheumatology and Immunology Center   (Netherlands)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^f ABBVIE INC   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL OUTCOME; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; POST HOC ANALYSIS; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

ADALIMUMAB; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85041540236     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211871     Document Type: Article

References (8)

1. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
2. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
3. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71.
4. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321-32.
5. Bykerk VP, Massarotti EM. The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology 2012;51(suppl 6):vi16-vi20.
6. Baron G, Ravaud P, Samson A, et al. Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: a simulation study. Arthritis Rheum 2008;59:25-31.
7. Smolen JS, Aletaha D, Grisar JC, et al. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010;69:1058-64.
8. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.